REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company’s new ...

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the ...

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company’s common stock will continue to be listed and ...

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company's common stock will continue to be listed and t ...

Shares of Plus Therapeutics, Inc. (PSTV) were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases (“LM”) in patients with lung cancer. The stock continued to gain another 51.4% in after-hours trading following the news announcement.The FDA grants ODD to support the development of medicines for rare disorders that affect fewer than 200, ...

Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform techno ...

HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer. "Receiving Orphan Dru ...

HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said ...

AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ReSPECT-LM single-dose escalation trial assessed the safety, tolerability, and potential efficacy of intratheca ...

Core Insights - Plus Therapeutics, Inc. has appointed Russell Bradley as President and General Manager of its subsidiary CNSide Diagnostics, LLC, aiming to enhance its operations in the diagnostic landscape for CNS cancers [2][3] - The company has also appointed Dr. Marc Hedrick, Mr. Rick Hawkins, and Mr. Russell Bradley to the CNSide Board of Directors, with Dr. Jonathan Stein as the new Medical Director [2][3] Company Developments - Russell Bradley brings over 30 years of experience in diagnostics and life sciences, having held senior roles at Abbott Laboratories, Luminex Corporation, and Beckman Coulter, and is expected to make an immediate impact on CNSide [3] - The immediate priority for CNSide Diagnostics is to support early access and initial launch plans in the U.S. for its diagnostic tools targeting leptomeningeal disease [4] Product and Market Focus - CNSide Diagnostics is focused on developing proprietary laboratory-developed tests to identify tumor cells that have metastasized to the central nervous system, particularly for patients with carcinomas and melanomas [6] - The CNSide platform includes four laboratory-developed tests for treatment selection and monitoring of patients with leptomeningeal metastases, utilizing both cellular and molecular assays [7][8] Industry Context - Leptomeningeal metastases (LM) is a rare but serious complication of cancer, affecting approximately 5% of cancer patients, with a particularly high incidence in breast cancer patients [5] - There are currently no FDA-approved therapies specifically for LM patients, highlighting a significant unmet medical need in this area [5]